BioSpace News Archive

DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.

GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa.

Vitrolife AB entered into a definitive agreement to acquire 100% of the shares in Igenomix S.L.[1] from EQT and other shareholders.

nference, the AI-driven health technology company, today announced publication of a preprint study in bioRxiv that found the genetic alteration of some linear peptides expressed specifically in the human heart are mimicked by the SARS-CoV-2 polyprotein (replicase).

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the study design for SAPPHIRE, a Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent myostatin.

Quidel Corporation issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘Anvisa’) has granted an exceptional authorisation for Illuccix® (TLX591-CDx) the Company’s lead prostate cancer imaging product.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the novel drug olverembatinib has been approved by the China National Medical Products Administration (NMPA).

Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.

Helix BioPharma Corp. is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021.